- Home
- WDH vs LXEO Comparison
WDH vs LXEO Comparison
Compare WDH & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WDH | LXEO |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.8M | 396.5M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | WDH | LXEO |
|---|---|---|
| Price | $1.12 | $4.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 140.9K | ★ 1.0M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.71 | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $3.91 |
| 52 Week High | $2.18 | $10.99 |
Technical Indicators
Market Signals| Indicator | WDH | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 33.71 | 47.48 |
| Support Level | $1.10 | $4.30 |
| Resistance Level | $1.32 | $5.36 |
| Average True Range (ATR) | 0.04 | 0.35 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 3.55 | 26.02 |
Price Performance
Historical ComparisonAbout WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. The Company is mainly engaged in operating an independent third-party insurance platform dedicated to providing insurance and healthcare service. The Companies main businesses are the insurance marketplace, medical crowdfunding, and mutual aid. The companies reportable segments are Insurance, Crowdfunding and Others.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.